<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02021526</url>
  </required_header>
  <id_info>
    <org_study_id>PASCG1D2014</org_study_id>
    <nct_id>NCT02021526</nct_id>
  </id_info>
  <brief_title>Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D)</brief_title>
  <official_title>Treatment Development of Triheptanoin for Glucose Transporter Type I Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juan Pascual</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-site, open-label, phase II trial of C7, a food supplement or medical food,
      for the development of treatment outcome measures for glucose transporter type I deficiency
      (G1D). The primary outcome measures are: 1. Safety and tolerability of C7 as measured by
      changes in comprehensive blood work, including lipid and free fatty acid panels,
      self-reported side effects and clinical exam; 2. Changes in brain metabolic rate by MRI and
      EEG measurements during C7 treatment; and 3. Maintenance of ketosis in G1D patients on
      ketogenic diet, as measured by serial ketone levels during treatment initiation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in risk for Metabolic Syndrome</measure>
    <time_frame>Baseline, 6 months, 9 months</time_frame>
    <description>Triglycerides, lipid levels, and cholesterol are measured to evaluate change in risk of metabolic syndrome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change on Biomarkers</measure>
    <time_frame>Baseline, 6 months, 9 months</time_frame>
    <description>EEG and brain metabolic rate will be measured at three time points. Changes in these biomarkers indicate the utilization of triheptanoin in brain metabolism</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Ketosis</measure>
    <time_frame>baseline, 6 months, 9 months</time_frame>
    <description>Safety blood work (described in the first outcome measure) is measured along with ketone levels and EEG to confirm that triheptanoin is safe and does not break ketosis in patients on the ketogenic diet</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Glucose Transporter Type 1 Deficiency Syndrome</condition>
  <condition>Glut1 Deficiency Syndrome</condition>
  <arm_group>
    <arm_group_label>No Dietary Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients currently on no dietary therapy will receive triheptanoin (C7 oil), dosed at 1 g/kg body weight and divided into 4 doses daily, administered for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketogenic Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients on ketogenic diet will receive triheptanoin (C7 oil) in place of their usual fat intake, at a dose sufficient to maintain their ketogenic diet ratio (based on patient weight and current ratio). Patients will receive triheptanoin for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triheptanoin</intervention_name>
    <description>Triheptanoin (C7 oil) is a 7-carbon medium chain triglyceride.</description>
    <arm_group_label>No Dietary Therapy</arm_group_label>
    <arm_group_label>Ketogenic Diet</arm_group_label>
    <other_name>C7</other_name>
    <other_name>Heptanoate</other_name>
    <other_name>Heptanoic Acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis or suspected diagnosis of glucose transporter type I deficiency (G1D).

          -  On stable ketogenic diet at a ratio between 1:2.5 and 1:4 OR Stable on no dietary
             therapy

          -  Males and females 30 months to 55 years old, inclusive.

        Exclusion Criteria:

          -  Subjects with a history of life-threatening seizure episodes, including but not
             limited to status epilepticus and cardiac arrest.

          -  Subjects with a BMI (body mass index) greater than or equal to 30 will be excluded.

          -  Subjects currently on dietary therapy other than ketogenic diet (i.e., medium chain
             triglyceride-supplemented diets, Atkins diet, low glycemic index diet, etc.).

          -  Women who are pregnant or breast-feeding may not participate. Women who plan to become
             pregnant during the course of the study, or who are unwilling to use birth control to
             prevent pregnancy (including abstinence) may not participate.

          -  Allergy/sensitivity to triheptanoin.

          -  Previous treatment with triheptanoin.

          -  Treatment with medium chain triglycerides in the last 30 days.

          -  Subjects exhibiting signs of dementia, or diagnosed with any degenerative brain
             disorder (such as Alzheimer's disease) that would confound assessment of cognitive
             changes, in the opinion of the investigator.

          -  Active drug or alcohol use or dependence that, in the opinion of the investigator,
             would interfere with adherence to study requirements.

          -  Patients with metal implants, experience claustrophobia, or who are behaviorally
             unable to be still for MRS (magnetic resonance spectroscopy) imaging (not due to
             seizures) will be excluded from the imaging portion of the research.

          -  Inability or unwillingness of subject or legal guardian/representative to give written
             informed consent, or assent for children age 10-17.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Months</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Pascual, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dorothy Kelly, MA</last_name>
    <email>rare.diseases@utsouthwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.g1dregistry.org</url>
    <description>The G1D Registry</description>
  </link>
  <link>
    <url>http://www.utsouthwestern.edu/education/medical-school/departments/neurology/programs/rare-brain-disorders/clinical-trials.html</url>
    <description>The Rare Brain Disorders Program at UT Southwestern: Clinical Research Studies</description>
  </link>
  <reference>
    <citation>Marin-Valencia I, Good LB, Ma Q, Malloy CR, Pascual JM. Heptanoate as a neural fuel: energetic and neurotransmitter precursors in normal and glucose transporter I-deficient (G1D) brain. J Cereb Blood Flow Metab. 2013 Feb;33(2):175-82. doi: 10.1038/jcbfm.2012.151. Epub 2012 Oct 17.</citation>
    <PMID>23072752</PMID>
  </reference>
  <reference>
    <citation>Marin-Valencia I, Good LB, Ma Q, Duarte J, Bottiglieri T, Sinton CM, Heilig CW, Pascual JM. Glut1 deficiency (G1D): epilepsy and metabolic dysfunction in a mouse model of the most common human phenotype. Neurobiol Dis. 2012 Oct;48(1):92-101. doi: 10.1016/j.nbd.2012.04.011. Epub 2012 Apr 23.</citation>
    <PMID>22683290</PMID>
  </reference>
  <reference>
    <citation>Jeffrey FM, Marin-Valencia I, Good LB, Shestov AA, Henry PG, Pascual JM, Malloy CR. Modeling of brain metabolism and pyruvate compartmentation using (13)C NMR in vivo: caution required. J Cereb Blood Flow Metab. 2013 Aug;33(8):1160-7. doi: 10.1038/jcbfm.2013.67. Epub 2013 May 8.</citation>
    <PMID>23652627</PMID>
  </reference>
  <reference>
    <citation>Xu F, Liu P, Pascual JM, Xiao G, Lu H. Effect of hypoxia and hyperoxia on cerebral blood flow, blood oxygenation, and oxidative metabolism. J Cereb Blood Flow Metab. 2012 Oct;32(10):1909-18. doi: 10.1038/jcbfm.2012.93. Epub 2012 Jun 27.</citation>
    <PMID>22739621</PMID>
  </reference>
  <reference>
    <citation>Marin-Valencia I, Good LB, Ma Q, Jeffrey FM, Malloy CR, Pascual JM. High-resolution detection of ¹³C multiplets from the conscious mouse brain by ex vivo NMR spectroscopy. J Neurosci Methods. 2012 Jan 15;203(1):50-5. doi: 10.1016/j.jneumeth.2011.09.006. Epub 2011 Sep 17.</citation>
    <PMID>21946227</PMID>
  </reference>
  <reference>
    <citation>Marin-Valencia I, Roe CR, Pascual JM. Pyruvate carboxylase deficiency: mechanisms, mimics and anaplerosis. Mol Genet Metab. 2010 Sep;101(1):9-17. doi: 10.1016/j.ymgme.2010.05.004. Epub 2010 Jun 9. Review.</citation>
    <PMID>20598931</PMID>
  </reference>
  <reference>
    <citation>Pérez-Dueñas B, Prior C, Ma Q, Fernández-Alvarez E, Setoain X, Artuch R, Pascual JM. Childhood chorea with cerebral hypotrophy: a treatable GLUT1 energy failure syndrome. Arch Neurol. 2009 Nov;66(11):1410-4. doi: 10.1001/archneurol.2009.236.</citation>
    <PMID>19901175</PMID>
  </reference>
  <reference>
    <citation>Pascual JM, Campistol J, Gil-Nagel A. Epilepsy in inherited metabolic disorders. Neurologist. 2008 Nov;14(6 Suppl 1):S2-S14. doi: 10.1097/01.nrl.0000340787.30542.41. Review.</citation>
    <PMID>19225367</PMID>
  </reference>
  <reference>
    <citation>Pascual JM, Wang D, Lecumberri B, Yang H, Mao X, Yang R, De Vivo DC. GLUT1 deficiency and other glucose transporter diseases. Eur J Endocrinol. 2004 May;150(5):627-33. Review.</citation>
    <PMID>15132717</PMID>
  </reference>
  <reference>
    <citation>Pascual JM, Wang D, Yang R, Shi L, Yang H, De Vivo DC. Structural signatures and membrane helix 4 in GLUT1: inferences from human blood-brain glucose transport mutants. J Biol Chem. 2008 Jun 13;283(24):16732-42. doi: 10.1074/jbc.M801403200. Epub 2008 Apr 3.</citation>
    <PMID>18387950</PMID>
  </reference>
  <reference>
    <citation>Pascual JM, Wang D, Hinton V, Engelstad K, Saxena CM, Van Heertum RL, De Vivo DC. Brain glucose supply and the syndrome of infantile neuroglycopenia. Arch Neurol. 2007 Apr;64(4):507-13. Epub 2007 Feb 12.</citation>
    <PMID>17296829</PMID>
  </reference>
  <reference>
    <citation>Pascual JM. [Glucose transport hereditary diseases]. Med Clin (Barc). 2006 Nov 11;127(18):709-14. Spanish.</citation>
    <PMID>17169300</PMID>
  </reference>
  <reference>
    <citation>Wang D, Pascual JM, Yang H, Engelstad K, Mao X, Cheng J, Yoo J, Noebels JL, De Vivo DC. A mouse model for Glut-1 haploinsufficiency. Hum Mol Genet. 2006 Apr 1;15(7):1169-79. Epub 2006 Feb 23.</citation>
    <PMID>16497725</PMID>
  </reference>
  <reference>
    <citation>Wang D, Pascual JM, Yang H, Engelstad K, Jhung S, Sun RP, De Vivo DC. Glut-1 deficiency syndrome: clinical, genetic, and therapeutic aspects. Ann Neurol. 2005 Jan;57(1):111-8.</citation>
    <PMID>15622525</PMID>
  </reference>
  <reference>
    <citation>Pascual JM, Lecumberri B, Wang D, Yang R, Engelstad K, De Vivo DC. [Type 1 glucose transporter (Glut1) deficiency: manifestations of a hereditary neurological syndrome]. Rev Neurol. 2004 May 1-15;38(9):860-4. Review. Spanish.</citation>
    <PMID>15152356</PMID>
  </reference>
  <reference>
    <citation>Wang D, Pascual JM, Iserovich P, Yang H, Ma L, Kuang K, Zuniga FA, Sun RP, Swaroop KM, Fischbarg J, De Vivo DC. Functional studies of threonine 310 mutations in Glut1: T310I is pathogenic, causing Glut1 deficiency. J Biol Chem. 2003 Dec 5;278(49):49015-21. Epub 2003 Sep 16.</citation>
    <PMID>13129919</PMID>
  </reference>
  <reference>
    <citation>Pascual JM, Van Heertum RL, Wang D, Engelstad K, De Vivo DC. Imaging the metabolic footprint of Glut1 deficiency on the brain. Ann Neurol. 2002 Oct;52(4):458-64.</citation>
    <PMID>12325075</PMID>
  </reference>
  <reference>
    <citation>Iserovich P, Wang D, Ma L, Yang H, Zuniga FA, Pascual JM, Kuang K, De Vivo DC, Fischbarg J. Changes in glucose transport and water permeability resulting from the T310I pathogenic mutation in Glut1 are consistent with two transport channels per monomer. J Biol Chem. 2002 Aug 23;277(34):30991-7. Epub 2002 May 24.</citation>
    <PMID>12032147</PMID>
  </reference>
  <reference>
    <citation>De Vivo DC, Wang D, Pascual JM, Ho YY. Glucose transporter protein syndromes. Int Rev Neurobiol. 2002;51:259-88. Review.</citation>
    <PMID>12420362</PMID>
  </reference>
  <reference>
    <citation>Brockmann K, Wang D, Korenke CG, von Moers A, Ho YY, Pascual JM, Kuang K, Yang H, Ma L, Kranz-Eble P, Fischbarg J, Hanefeld F, De Vivo DC. Autosomal dominant glut-1 deficiency syndrome and familial epilepsy. Ann Neurol. 2001 Oct;50(4):476-85.</citation>
    <PMID>11603379</PMID>
  </reference>
  <reference>
    <citation>Marin-Valencia I, Yang C, Mashimo T, Cho S, Baek H, Yang XL, Rajagopalan KN, Maddie M, Vemireddy V, Zhao Z, Cai L, Good L, Tu BP, Hatanpaa KJ, Mickey BE, Matés JM, Pascual JM, Maher EA, Malloy CR, Deberardinis RJ, Bachoo RM. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 2012 Jun 6;15(6):827-37. doi: 10.1016/j.cmet.2012.05.001. Erratum in: Cell Metab. 2012 Nov 7;16(5):686.</citation>
    <PMID>22682223</PMID>
  </reference>
  <reference>
    <citation>Maher EA, Marin-Valencia I, Bachoo RM, Mashimo T, Raisanen J, Hatanpaa KJ, Jindal A, Jeffrey FM, Choi C, Madden C, Mathews D, Pascual JM, Mickey BE, Malloy CR, DeBerardinis RJ. Metabolism of [U-13 C]glucose in human brain tumors in vivo. NMR Biomed. 2012 Nov;25(11):1234-44. doi: 10.1002/nbm.2794. Epub 2012 Mar 15.</citation>
    <PMID>22419606</PMID>
  </reference>
  <reference>
    <citation>Marin-Valencia I, Cho SK, Rakheja D, Hatanpaa KJ, Kapur P, Mashimo T, Jindal A, Vemireddy V, Good LB, Raisanen J, Sun X, Mickey B, Choi C, Takahashi M, Togao O, Pascual JM, Deberardinis RJ, Maher EA, Malloy CR, Bachoo RM. Glucose metabolism via the pentose phosphate pathway, glycolysis and Krebs cycle in an orthotopic mouse model of human brain tumors. NMR Biomed. 2012 Oct;25(10):1177-86. doi: 10.1002/nbm.2787. Epub 2012 Mar 1.</citation>
    <PMID>22383401</PMID>
  </reference>
  <reference>
    <citation>Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, Yang XL, Mashimo T, Raisanen JM, Marin-Valencia I, Pascual JM, Madden CJ, Mickey BE, Malloy CR, Bachoo RM, Maher EA. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med. 2012 Jan 26;18(4):624-9. doi: 10.1038/nm.2682.</citation>
    <PMID>22281806</PMID>
  </reference>
  <reference>
    <citation>Choi C, Ganji SK, DeBerardinis RJ, Dimitrov IE, Pascual JM, Bachoo R, Mickey BE, Malloy CR, Maher EA. Measurement of glycine in the human brain in vivo by 1H-MRS at 3 T: application in brain tumors. Magn Reson Med. 2011 Sep;66(3):609-18. doi: 10.1002/mrm.22857. Epub 2011 Mar 9.</citation>
    <PMID>21394775</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2013</study_first_submitted>
  <study_first_submitted_qc>December 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2013</study_first_posted>
  <last_update_submitted>December 26, 2013</last_update_submitted>
  <last_update_submitted_qc>December 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Juan Pascual</investigator_full_name>
    <investigator_title>Associate Professor, Director of the Rare Brain Disorders Program</investigator_title>
  </responsible_party>
  <keyword>G1D</keyword>
  <keyword>Glut1 Deficiency</keyword>
  <keyword>Glucose Transporter Type 1 Deficiency</keyword>
  <keyword>Glucose Transporter Type I Deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Carbohydrate Metabolism, Inborn Errors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

